HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
Conditions
Brief summary
Requests for single patient expanded access to tipifarnib may be considered for adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL). To request access, use Responsible Party contact information provided in this record. Expanded access for tipifarnib is only available in the United States.
Interventions
DRUGTipifarnib
Tipifarnib
Sponsors
Kura Oncology, Inc.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Inclusion/
Exclusion criteria
Diagnosed with HRAS mutations or peripheral T Cell Lymphoma (PTCL). Adult, ages 18+. Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition. Is ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations. Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology
Contacts
CONTACTKura Medical Information
Outcome results
None listed